Susquehanna Fundamental Investments LLC Has $3.14 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Susquehanna Fundamental Investments LLC lifted its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 106.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,833 shares of the medical device company’s stock after purchasing an additional 40,128 shares during the quarter. Susquehanna Fundamental Investments LLC owned 0.12% of Tandem Diabetes Care worth $3,136,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Tandem Diabetes Care by 0.4% in the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after purchasing an additional 30,664 shares in the last quarter. Jennison Associates LLC grew its stake in shares of Tandem Diabetes Care by 98.1% in the first quarter. Jennison Associates LLC now owns 2,556,124 shares of the medical device company’s stock valued at $90,512,000 after buying an additional 1,265,534 shares in the last quarter. Fred Alger Management LLC increased its holdings in Tandem Diabetes Care by 45.2% during the second quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock worth $87,595,000 after buying an additional 677,036 shares during the last quarter. Bellevue Group AG raised its position in Tandem Diabetes Care by 2.0% during the first quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company’s stock worth $71,949,000 after acquiring an additional 39,571 shares in the last quarter. Finally, Brown Capital Management LLC lifted its stake in Tandem Diabetes Care by 29.9% in the first quarter. Brown Capital Management LLC now owns 954,567 shares of the medical device company’s stock valued at $33,801,000 after acquiring an additional 219,940 shares during the last quarter.

Tandem Diabetes Care Price Performance

Tandem Diabetes Care stock opened at $42.41 on Tuesday. The firm has a market cap of $2.78 billion, a PE ratio of -19.54 and a beta of 1.32. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.05 and a quick ratio of 2.38. The stock’s fifty day moving average price is $42.18 and its two-hundred day moving average price is $41.27. Tandem Diabetes Care, Inc. has a one year low of $13.82 and a one year high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. The company had revenue of $221.90 million for the quarter, compared to analysts’ expectations of $205.63 million. During the same quarter last year, the business earned ($0.30) earnings per share. Tandem Diabetes Care’s revenue was up 13.3% on a year-over-year basis. As a group, research analysts expect that Tandem Diabetes Care, Inc. will post -1.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TNDM shares. Piper Sandler restated an “overweight” rating and set a $55.00 price objective (up from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Morgan Stanley reaffirmed an “equal weight” rating and issued a $45.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, September 23rd. Robert W. Baird boosted their target price on Tandem Diabetes Care from $36.00 to $39.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, UBS Group raised shares of Tandem Diabetes Care to a “hold” rating in a research report on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.36.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.